SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”...
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.